Literature DB >> 9733880

A functionally distinct TATA box required for late progression through the Epstein-Barr virus life cycle.

T R Serio1, N Cahill, M E Prout, G Miller.   

Abstract

During EBV infection, lytic DNA replication activates late gene expression in trans via an uncharacterized pathway. In this study, we mapped the target of this regulatory cascade to a variant TATA box (TATTAAA) and the 3' flanking region within the core promoter of the BcLF1 gene. The inherent late activity of this core promoter is, surprisingly, disrupted by a heterologous enhancer, suggesting that late gene expression is regulated through core promoter sequences located in a transcriptionally inert environment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733880      PMCID: PMC110205     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

2.  The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.

Authors:  T Ragoczy; L Heston; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Mapping of Epstein-Barr virus proteins on the genome by translation of hybrid-selected RNA from induced P3HR1 cells and induced Raji cells.

Authors:  R Seibl; H Wolf
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

5.  trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment.

Authors:  K Takada; N Shimizu; S Sakuma; Y Ono
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

6.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

7.  Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.

Authors:  A K Datta; R E Hood
Journal:  Virology       Date:  1981-10-15       Impact factor: 3.616

8.  The control of herpes simplex virus type-1 late gene transcription: a 'TATA-box'/cap site region is sufficient for fully efficient regulated activity.

Authors:  P A Johnson; R D Everett
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

9.  gamma 2-Thymidine kinase chimeras are identically transcribed but regulated a gamma 2 genes in herpes simplex virus genomes and as beta genes in cell genomes.

Authors:  S Silver; B Roizman
Journal:  Mol Cell Biol       Date:  1985-03       Impact factor: 4.272

10.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  31 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  The Epstein-Barr virus BcRF1 gene product is a TBP-like protein with an essential role in late gene expression.

Authors:  Henri Gruffat; Faouzi Kadjouf; Bernard Mariamé; Evelyne Manet
Journal:  J Virol       Date:  2012-03-28       Impact factor: 5.103

3.  Lytic cycle gene regulation of Epstein-Barr virus.

Authors:  Wolfgang Amon; Ulrich K Binné; Helen Bryant; Peter J Jenkins; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  ORF18 is a transfactor that is essential for late gene transcription of a gammaherpesvirus.

Authors:  Vaithilingaraja Arumugaswami; Ting-Ting Wu; DeeAnn Martinez-Guzman; Qingmei Jia; Hongyu Deng; Nichole Reyes; Ren Sun
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.

Authors:  Jill Countryman; Lyndle Gradoville; Sumita Bhaduri-McIntosh; Jianjiang Ye; Lee Heston; Sarah Himmelfarb; Duane Shedd; George Miller
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

6.  Quantitative Analysis of the KSHV Transcriptome Following Primary Infection of Blood and Lymphatic Endothelial Cells.

Authors:  A Gregory Bruce; Serge Barcy; Terri DiMaio; Emilia Gan; H Jacques Garrigues; Michael Lagunoff; Timothy M Rose
Journal:  Pathogens       Date:  2017-03-19

7.  Unconventional sequence requirement for viral late gene core promoters of murine gammaherpesvirus 68.

Authors:  Elaine Wong-Ho; Ting-Ting Wu; Zoe H Davis; Bingqing Zhang; Jian Huang; Hao Gong; Hongyu Deng; Fenyong Liu; Britt Glaunsinger; Ren Sun
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

8.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 9.  An Epigenetic Journey: Epstein-Barr Virus Transcribes Chromatinized and Subsequently Unchromatinized Templates during Its Lytic Cycle.

Authors:  Adityarup Chakravorty; Bill Sugden; Eric C Johannsen
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

10.  S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription.

Authors:  Yoshitaka Sato; Takahiro Watanabe; Chihiro Suzuki; Yuichi Abe; H M Abdullah Al Masud; Tomoki Inagaki; Masahiro Yoshida; Takeshi Suzuki; Fumi Goshima; Jun Adachi; Takeshi Tomonaga; Takayuki Murata; Hiroshi Kimura
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.